|Description||MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.|
|Synonyms||MRS-2578; MRS2578; MRS 2578.|
PSB 0739 is a highly potent, direct‐acting and reversible P2Y12 receptor antagonist (Ki = 24.9 nM). Unlike clopidogrel, it does not require bioactivation. P2Y12...
NF 157 is a P2Y11 receptor antagonist with IC50 value of 463 nM. It inhibits NAD+-induced activation of human granulocytes.
αβ-methylene ATP, a phosphonic analog of ATP, is an agonist of P2X purinoceptors P2X1 and P2X3 (EC50 = ~1 µM) and is ~1,000-fold less potent at P2X2, P2X recept...
Regrelor is a P2Y12 antagonist. In Dec 2008, Phase-II for Thrombosis in USA was discontinued.
Clopidogrel, a thienopyridine derivative, could be used in the prevention and treatment of sorts of arterial circulation disorders caused by platelet aggregatio...
The sodium salt of Suramin which is a P2 purinergic antagonist and has been also found to have the effect in blocking the G protein binds to GPCRs so that it wa...
MRS 2690 is a potent P2Y14 receptor agonist (EC50 = 49 nM), with 7-fold higher potency than UDP-glucose.
INS-37217, also known as Denufosol, is a long- acting P2Y2 receptor agonist potentially for the treatment of cystic fibrosis. INS-37217 exhibits an EC50 of ~10 ...